NCMT Technique and Jodhpur Technique and Excimer Laser in Treatment of Non Vitiligo Leucoderma

Efficacy and Safety of Melanocyte Keratinocyte Transplantation Procedure Plus 308-nm Excimer Laser in the Treatment of Non-Vitiligo Leukoderma

This study aims to compare the efficacy and safety of Melanocyte Keratinocyte Transplantation Procedure (MKTP) combined with 308-nm excimer laser versus Jodhpur technique combined with 308-nm excimer laser in the treatment of stable non-vitiligo leukoderma. Twenty-two patients with stable depigmented lesions will be enrolled. In each patient, two comparable lesions will be treated using different techniques. Clinical outcomes including percentage of repigmentation, color match, time to onset of repigmentation, complications, and histological changes will be assessed during follow-up to determine the optimal surgical treatment approach for non-vitiligo leukoderma.

Study Overview

• Status: Not yet recruiting
• Conditions: Leukoderma
• Intervention / Treatment: Procedure: Melanocyte Keratinocyte Transplantation Procedure (MKTP); Device: 308-nm Excimer Laser; Procedure: Jodhpur Technique

• Study Type: Interventional
• Enrollment (Estimated): 22
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Mohamed Mahmoud; Phone Number: +201091865997; Email: mas912m@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age 18 to 60 years.
• Clinically diagnosed stable non-vitiligo leukoderma.
• Stable lesion(s) for at least 6 months with no progression.
• Inadequate response to conventional medical therapy.
• Presence of two comparable lesions
• Willingness to participate and provide written informed consent.

Exclusion Criteria:

• Vitiligo or suspected active vitiligo.
• History of keloid or hypertrophic scar formation.
• Active infection at donor or recipient sites.
• Bleeding disorders or anticoagulant therapy that cannot be safely discontinued.
• Pregnancy or lactation.
• Immunosuppression or uncontrolled systemic disease.
• Inability to comply with follow-up visits.
• Unrealistic expectations regarding treatment outcome.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MKTP+ excimer laser; Melanocyte Keratinocyte Transplantation Procedure followed by 308-nm excimer laser therapy	Procedure: Melanocyte Keratinocyte Transplantation Procedure (MKTP); Autologous melanocyte-keratinocyte cell suspension prepared using enzymatic separation and applied to a dermabraded recipient site.; Device: 308-nm Excimer Laser; Excimer laser therapy initiated approximately 14 days after surgery, administered twice weekly for 12-16 weeks with dose adjustment according to erythema response
Experimental: Jodhpur Technique + Excimer Laser; Jodhpur technique followed by 308-nm excimer laser therapy	Device: 308-nm Excimer Laser; Excimer laser therapy initiated approximately 14 days after surgery, administered twice weekly for 12-16 weeks with dose adjustment according to erythema response; Procedure: Jodhpur Technique; Autologous non-cultured epidermal cell transfer technique using dermabraded donor skin particles applied directly to the recipient site without enzymatic processing

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Mean Percentage Repigmentation of Target Lesions	6 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Time to Onset of Repigmentation	Up to 6 months
Color Match Assessment	6 months

Collaborators and Investigators

• Sponsor: Al-Azhar University

Study record dates

Study Major Dates

• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): September 1, 2027

Study Registration Dates

• First Submitted: June 17, 2026
• First Submitted That Met QC Criteria: June 17, 2026
• First Posted (Actual): June 23, 2026

Study Record Updates

• Last Update Posted (Actual): June 23, 2026
• Last Update Submitted That Met QC Criteria: June 17, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Hypopigmentation; Pigmentation Disorders; Skin and Connective Tissue Diseases; Vitiligo; Equipment and Supplies; Lasers; Optical Devices; Radiation Equipment and Supplies; Lasers, Excimer
• Other Study ID Numbers: RESEARCH/AZ.AST./DVA021/10/265

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No